Change search
ReferencesLink to record
Permanent link

Direct link
Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial
Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad, Inst Clin Sci,Dept Surg, S-41345 Gothenburg, Sweden.
Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad, Inst Clin Sci,Dept Oncol, S-41345 Gothenburg, Sweden.
St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden.
Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad, Inst Clin Sci,Tranplant Inst, S-41345 Gothenburg, Sweden.
Show others and affiliations
2014 (English)In: Trials, ISSN 1745-6215, Vol. 15, 317- p.Article in journal (Refereed) Published
Abstract [en]

Background: Uveal melanoma is the most common primary intraocular malignancy in adults. Despite successful control of the primary tumor, metastatic disease will ultimately develop in approximately 50% of patients, with the liver being the most common site for metastases. The median survival for patients with liver metastases is between 6 and 12 months, and no treatment has in randomized trials ever been shown to prolong survival. A previous phase II trial using isolated hepatic perfusion (IHP) has suggested a 14-month increase in overall survival compared with a historic control group consisting of the longest surviving patients in Sweden during the same time period (26 versus 12 months). Methods/Design: This is the protocol for a multicenter phase III trial randomizing patients with isolated liver metastases of uveal melanoma to IHP or best alternative care (BAC). Inclusion criteria include liver metastases (verified by biopsy) and no evidence of extra-hepatic tumor manifestations by positron emission tomography-computed tomography (PET-CT). The primary endpoint is overall survival at 24 months, with secondary endpoints including response rate, progression-free survival, and quality of life. The planned sample size is 78 patients throughout five years. Discussion: Patients with isolated liver metastases of uveal melanoma origin have a short expected survival and no standard treatment option exists. This is the first randomized clinical trial to evaluate IHP as a treatment option with overall survival being the primary endpoint.

Place, publisher, year, edition, pages
2014. Vol. 15, 317- p.
Keyword [en]
Uveal melanoma, Liver metastases, Isolated hepatic perfusion, Regional treatment
National Category
Cancer and Oncology
URN: urn:nbn:se:umu:diva-93494DOI: 10.1186/1745-6215-15-317ISI: 000340787700001PubMedID: 25106493OAI: diva2:761984

Errata Trials (2015), 16, 334. DOI: 10.1186/s13063-015-0809-8

Available from: 2014-11-10 Created: 2014-09-23 Last updated: 2015-08-31Bibliographically approved

Open Access in DiVA

fulltext(285 kB)64 downloads
File information
File name FULLTEXT01.pdfFile size 285 kBChecksum SHA-512
Type fulltextMimetype application/pdf
Errata(352 kB)2 downloads
File information
File name ATTACHMENT01.pdfFile size 352 kBChecksum SHA-512
Type attachmentMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Ljuslinder, Ingrid
By organisation
In the same journal
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 64 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 65 hits
ReferencesLink to record
Permanent link

Direct link